Structure Therapeutics Inc. Increase (Decrease) in Accounts Payable
Structure Therapeutics Inc. (GPCR) reported Increase (Decrease) in Accounts Payable of -$1.66 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayable · last filed 2026-08-06
- Structure Therapeutics Inc. increase (decrease) in accounts payable for the quarter ending 2026-06-30 was $3.31M, a 1081.79% increase year-over-year.
- Structure Therapeutics Inc. increase (decrease) in accounts payable for the quarter ending 2026-03-31 was -$4.97M, a 824.05% decline year-over-year.
- Structure Therapeutics Inc. increase (decrease) in accounts payable for the quarter ending 2025-12-31 was -$5.01M.
- Structure Therapeutics Inc. increase (decrease) in accounts payable for the quarter ending 2025-09-30 was $8.81M, a 39.76% increase year-over-year.
- Structure Therapeutics Inc. increase (decrease) in accounts payable for fiscal 2025 was $4.76M, a 44.09% increase from fiscal 2024.
- Structure Therapeutics Inc. increase (decrease) in accounts payable for fiscal 2024 was $3.31M.
- Structure Therapeutics Inc. increase (decrease) in accounts payable for fiscal 2023 was -$860.00K, a 139.94% decline from fiscal 2022.
- Structure Therapeutics Inc. increase (decrease) in accounts payable for fiscal 2022 was $2.15M.
| Period end | Increase (Decrease) in Accounts Payable 3 month | Increase (Decrease) in Accounts Payable 6 month | Increase (Decrease) in Accounts Payable 9 month | Increase (Decrease) in Accounts Payable 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$1.66M 10-Q · filed 2026-08-06 | -$6.67M derived: sum of 3 quarters · filed 2026-08-06 | $2.14M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$4.97M 10-Q · filed 2026-05-07 | -$9.97M derived: sum of 2 quarters · filed 2026-05-07 | -$1.17M derived: sum of 3 quarters · filed 2026-05-07 | -$888.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$5.01M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $3.80M derived: sum of 2 quarters · filed 2026-02-26 | $4.08M derived: sum of 3 quarters · filed 2026-08-06 | $4.76M 10-K · filed 2026-02-26 |
| 2025-09-30 | $8.81M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $9.09M derived: sum of 2 quarters · filed 2026-08-06 | $9.77M 10-Q · filed 2025-11-06 | $9.35M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $280.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $966.00K 10-Q · filed 2026-08-06 | $543.00K derived: sum of 3 quarters · filed 2026-08-06 | $6.84M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $686.00K 10-Q · filed 2026-05-07 | $263.00K derived: sum of 2 quarters · filed 2026-05-07 | $6.56M derived: sum of 3 quarters · filed 2026-05-07 | $2.17M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$423.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $5.88M derived: sum of 2 quarters · filed 2026-02-26 | $1.49M derived: sum of 3 quarters · filed 2026-02-26 | $3.31M 10-K · filed 2026-02-26 |
| 2024-09-30 | $6.30M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $1.91M derived: sum of 2 quarters · filed 2025-11-06 | $3.73M 10-Q · filed 2025-11-06 | $5.13M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | -$4.39M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -$2.57M 10-Q · filed 2025-08-06 | -$1.17M derived: sum of 3 quarters · filed 2026-02-26 | -$3.55M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $1.82M 10-Q · filed 2025-05-08 | $3.22M derived: sum of 2 quarters · filed 2026-02-26 | $837.00K derived: sum of 3 quarters · filed 2026-02-26 | $1.88M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $1.40M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$982.00K derived: sum of 2 quarters · filed 2026-02-26 | $63.00K derived: sum of 3 quarters · filed 2026-02-26 | -$860.00K 10-K · filed 2026-02-26 |
| 2023-09-30 | -$2.38M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$1.33M derived: sum of 2 quarters · filed 2024-11-13 | -$2.26M 10-Q · filed 2024-11-13 | -$2.38M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | $1.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $122.00K 10-Q · filed 2024-08-08 | -$2.00K derived: sum of 3 quarters · filed 2024-08-08 | $2.26M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$923.00K 10-Q · filed 2024-05-09 | -$1.05M derived: sum of 2 quarters · filed 2024-05-09 | $1.22M derived: sum of 3 quarters · filed 2024-05-09 | $2.79M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | -$124.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-08 | $2.14M derived: sum of 2 quarters · filed 2024-03-08 | $3.72M derived: sum of 3 quarters · filed 2024-03-08 | $2.15M 10-K · filed 2024-03-08 |
| 2022-09-30 | $2.27M derived: 10-Q 9 month − 10-Q/A 6 month · filed 2023-11-17 | $3.84M derived: sum of 2 quarters · filed 2023-11-17 | $2.28M 10-Q · filed 2023-11-17 | |
| 2022-06-30 | $1.57M derived: 10-Q/A 6 month − 10-Q 3 month · filed 2023-11-17 | $12.00K 10-Q/A · filed 2023-11-17 | ||
| 2022-03-31 | -$1.56M 10-Q · filed 2023-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |